Abstract
AbstractFailure to share and make use of existing knowledge, particularly negative research outcomes, has been recognized as one of the key sources of waste and inefficiency in the drug discovery and development process. In the field of antibiotic research, providing a platform where negative outcomes could be shared to prevent the vicious cycle of duplicating costly studies that produce the same negative results would greatly de-risk and accelerate the development of new antibiotics. Providing a legally supported framework that recognizes negative outcomes as intellectual contributions, which can subsequently be translated into a revenue-sharing model, may lead to more openness and value creation in support of a sustainable and responsible transformation of research into socially and economically beneficial innovations.
Funder
Norges Forskningsråd
Centre for Digital Life Norway https://www.digitallifenorway.org/
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology
Reference19 articles.
1. European Commission. Exploitation of IP for Industrial Innovation—Final Report. 2015. https://ec.europa.eu/docsroom/documents/13441/attachments/1/translations/en/renditions/native.
2. Mills RM. Why do drugs in development “fail” in clinical trials. Drug Discov Trends. 2016. https://www.drugdiscoverytrends.com/why-do-drugs-in-development-fail-in-clinical-trials/.
3. Macleod MR, et al. Biomedical research: increasing value, reducing waste. Lancet. 2014;6736:1–6.
4. Bogers M, et al. Open innovation: research, practices, and policies. Calif Manag Rev. 2018;60:5–16.
5. Joseph H. The open access movement grows up: taking stock of a revolution. PLoS Biol. 2013;11:1–3.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献